Niagen Bioscience, Inc.
NAGE Nasdaq· Medicinal Chemicals & Botanical Products
Last close · Oct 23, 2026
$2.43
KIRA · Stoqly’s AI analyst, in plain words
- Niagen Bioscience, Inc. had $129M of revenue in fiscal 2025, up 29.9% on the year before. Over five years, revenue changed +16.9% a year on average.
- Its operating margin was 12.6%, up 4.8 pts: of every 100 in sales, about 13 is left after running the business.
- Niagen Bioscience, Inc. made $17.4M of net profit in fiscal 2025.
- Niagen Bioscience, Inc. returned $0.3M to shareholders in fiscal 2025. The diluted share count rose 9.4%.
Market cap
$200M
P/E
13.5x
Revenue
$129M
Net income
$17.4M
Free cash flow
—
Operating margin
12.6%
Niagen Bioscience, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+29.9%
Yes. Sales grew 29.9% last year.
Does it make a profit?
13.4%
Yes. It keeps 13.4% of every sale as profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
13.5x
One share costs 13.5 times its yearly profit per share.
What Niagen Bioscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Niagen Bioscience, Inc.
- CIK
- 0001386570
Niagen Bioscience, Inc. · NAGE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $67.4M | $72.1M | $83.6M | $99.6M | $129M |
| Revenue growth | 13.8% | 6.8% | 16.0% | 19.2% | 29.9% |
| Net interest income | −$0.1M | $0.0M | $0.7M | — | — |
| Gross margin | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating margin | −40.1% | −25.9% | −6.7% | 7.8% | 12.6% |
| Net income | −$27.1M | −$16.5M | −$4.9M | $8.6M | $17.4M |
| Net margin | −40.2% | −23.0% | −5.9% | 8.6% | 13.4% |
| Diluted EPS | −$0.40 | −$0.24 | −$0.07 | $0.11 | $0.20 |
| Cash | |||||
| Cash from operations | −$24.2M | −$15.1M | $7.1M | $12.1M | $13.5M |
| Share buybacks | — | — | — | $0.0M | $0.3M |
| Share count change | 10.0% | 3.8% | 7.5% | 4.2% | 9.4% |
| Debt and strength | |||||
| Cash and short-term investments | $28.2M | $20.3M | $27.2M | $44.5M | $64.8M |
| Shareholders' equity | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
| Current ratio | 2.8x | 2.6x | 2.4x | 3.6x | 4.9x |
| Interest coverage | −492.2x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −112.7% | −54.8% | −17.3% | 22.9% | 28.3% |
| Return on tangible equity | −87.9% | −59.1% | −17.7% | 18.7% | 24.5% |
| Piotroski F-score | 4 | 3 | 5 | 6 | 5 |
| Altman Z'' | −7.8 | −8.8 | −7.4 | −1.3 | 3.4 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Niagen Bioscience, Inc. · NAGE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.43 a share, the company is worth $200M: 13.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001386570). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.